

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



BL

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/20, 11/00, C12Q 1/00, A61K 38/43	A1	(11) International Publication Number: WO 97/44445 (43) International Publication Date: 27 November 1997 (27.11.97)
(21) International Application Number: PCT/US97/08526 (22) International Filing Date: 20 May 1997 (20.05.97) (30) Priority Data: 08/652,964 24 May 1996 (24.05.96) US (71) Applicant: ALTUS BIOLOGICS INC. [US/US]; 40 Allston Street, Cambridge, MA 02139-4211 (US). (72) Inventor: KHALAF, Nazer, K.; 14 Lauf Street, Worcester, MA 01602 (US). (74) Agents: HALEY, James, F., Jr. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020-1104 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: CROSS-LINKED PROTEIN CRYSTAL FORMULATIONS AND THEIR USE AS CATALYSTS IN ORGANIC SOLVENTS		
(57) Abstract The present invention relates to the application of biocatalysis technology for performing selective chemical reactions. In one embodiment, this invention relates to cross-linked protein crystal formulations and their use as catalysts in chemical reactions involving organic solvents. This invention also provides methods for producing cross-linked protein crystal formulations and methods using them to optimize chemical reactions in organic solvents, including those used in industrial scale chemical processes.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AI.	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CROSSLINKED PROTEIN CRYSTAL FORMULATIONS
AND THEIR USE AS CATALYSTS IN ORGANIC SOLVENTS

TECHNICAL FIELD OF THE INVENTION

The present invention relates to the
5 application of biocatalysis technology for performing
selected chemical reactions. In one embodiment, this
invention relates to crosslinked protein crystal
formulations and their use as catalysts in chemical
reactions involving organic solvents. This invention
10 also provides methods for producing crosslinked protein
crystal formulations and methods using them to optimize
chemical reactions in organic solvents, including those
used in industrial scale chemical processes.

BACKGROUND OF THE INVENTION

15 The use of proteins, such as enzymes, as
catalysts in industrial-scale synthesis of specialty
chemicals and pharmaceuticals has received much
attention in recent years [K. Faber and M.C.R.
Franssen, Trends in Biochem. Tech., 11, pp. 461-70
20 (1993)]. Enzymes are recognized as useful tools for
accomplishing chemical reactions in a stereo-, regio-
and chemoselective manner. The ability of enzymes to
function under mild conditions, ease of disposal and

- 2 -

minimal waste production are further advantages associated with their use. Enzymes are also used for catalysis in organic solvents to solubilize substrates and products and to manipulate reaction kinetics and
5 equilibrium in order to increase product yield.

While enzymes offer impressive synthetic potential over current nonenzymatic technology, their commercial use has been limited by disadvantages such as poor stability, variability in performance,
10 difficulty of isolation and purification, difficulty in handling, high cost and long reaction times. Furthermore, organic solvents are often incompatible with enzymes, leading to enzyme degradation or inactivation [A.M. Klivanov, "Asymmetric
15 Transformations Catalyzed by Enzymes in Organic Solvents", Acc. Chem. Res., 23, pp. 114-20 (1990)]. In order for enzymes to function as viable industrial catalysts, they must be able to function without excessive intervention in the practical environments of
20 manufacturing processes. Such environments include polar and non-polar organic solvents and aqueous-organic solvent mixtures. The low activity of enzymes and their aversion to organic solvents have remained barriers to widespread use of these proteins in routine
25 organic syntheses. Even when such syntheses are catalyzed by enzymes, it is not unusual to see processes employing more enzyme than substrate by weight. See, for example, R. Bovera et al., Tetrahedron: Asymmetry, 2, pp. 931-38 (1991); Y.-F. Wang et al., J. Am. Chem. Soc., 110, pp. 7200-05
30 (1988); A. Palomaer et al., Chirality, 5, pp. 320-28

- 3 -

(1993) and V. Gotor et al., Tetrahedron, 47, pp. 9207-14 (1991).

Two methods designed to overcome these disadvantages -- enzyme purification and enzyme immobilization -- have addressed some of these disadvantages. However, they have not solved the problem of loss of enzyme activity or stability in organic solvents. Immobilization has actually exacerbated these problems by incurring higher costs and diluting the activity of the enzyme by the addition of support materials. Enzyme purification also incurs added cost and, in most cases fails to increase enzyme activity in organic solvents. For example, the potential synthetic benefits of purified lipases in organic solvents have not been realized [T. Nishio and M. Kamimura, Agric. Biol. Chem., 52, pp. 2631-32 (1988); T. Yamane et al., Biotechnol. Bioeng., 36, pp. 1063-69 (1990)]. The cost of purified lipases is higher than that of their crude counterparts, while their stability and activity in organic solvents is lower [R. Bovara et al., Biotechnol. Lett., 15, pp. 169-74 (1993); E. Wehtje et al., Biotechnol. Bioeng., 41, pp. 171-78 (1993); G. Ottolina et al., Biotechnol. Lett., 14, pp. 947-52 (1992)].

Recent studies have demonstrated that enzyme activity in organic solvents is intimately related to water content, size and morphology of the catalyst particles and the enzyme microenvironment [A.M. Klibanov, "Enzymatic Catalysis in Anhydrous Organic Solvents", Trends in Biochem. Sci., 14, pp. 141-44 (1989)]. These parameters have been adjusted by

- 4 -

preparing lyophilized complexes of enzymes with carbohydrates, organic buffers or salts [K. Dabulis and A.M. Klibanov, Biotechnol. Bioeng., 41, pp. 566-71 (1993); A.D. Blackwood et al., Biochim. Biophys. Acta, 1206, pp. 161-65 (1994); Y.L. Khmelnitsky et al., J. Am. Chem. Soc., 116, pp. 2647-48 (1994)]. However, despite the widespread use of lyophilization for preparation of enzymes for catalysis in organic solvents, its impact is not fully understood and, in some instances, it may cause significant reversible denaturation of enzymes [Dabulis and Klibanov, *supra*].

Other approaches to the problem of low enzyme activity in biotransformations involving organic solvents have included the use of surfactants. It has been reported that non-ionic surfactants added prior to immobilization of lipase into a photo-crosslinkable resin pre-polymer, or added to the reaction incubation mixture, increase enzyme activity [B. Nordvi and H. Holmsen, "Effect of Polyhydroxy Compounds on the activity of Lipase from Rhizopus arrhizus in Organic Solvent", in Biocatalysis in Non-Conventional Media, J. Tramper et al. (Ed.), pp. 355-61 (1992)].

Immobilized lipase enzymes prepared by application of a non-ionic surfactant (containing at least one fatty acid moiety) to a hydrophobic support prior to or simultaneously with application of the lipase enzyme demonstrate activity in enzymatic conversion processes comparable with conventional immobilized enzymes [PCT patent application WO 94/28118].

Surfactants have been said to reduce enzymatic activity of lipases [S. Bornemann et al.,

- 5 -

"The Effects of Surfactants on Lipase-Catalysed Hydrolysis of Esters: Activities and Stereo Selectivity", Biocatalysis, 11, pp. 191-221 (1994)]. Nevertheless, surfactants have been mixed with an aqueous solution of an enzyme, the mixture dewatered and the resulting enzyme preparation used as a catalyst said to have enhanced activity in organic solvents [PCT patent application WO 95/17504]. Surfactants or lipids have also been used to coat enzymes in order to solubilize them in organic solvents and, thus, increase chemical reaction rates [M. Goto et al., "Design of Surfactants Suitable for Surfactant-Coated Enzymes as Catalysts in Organic Media", J. Chem. Eng. Jpn., 26, pp. 109-11 (1993); N. Kamiya et al., "Surfactant-Coated Lipase Suitable for the Enzymatic Resolution of Methanol as a Biocatalyst in Organic Media", Biotechnol. Prog., 11, pp. 270-75 (1995)]. After this procedure, the enzymes become soluble in organic solvents. Enzyme complexes soluble in organics are also described in V.M. Paradkar and J.S. Dordick, J. Am. Chem. Soc., 116, pp. 5009-10 (1994) (proteases) and Y. Okahata et al., J. Org. Chem., 60, pp. 2240-50 (1995) (lipases).

The advent of crosslinked enzyme crystal ("CLEC™") technology provided a unique approach to solving the above-described disadvantages [N.L. St. Clair and M.A. Navia, J. Am. Chem. Soc., 114, pp. 7314-16 (1992)]. Crosslinked enzyme crystals retain their activity in environments that are normally incompatible with enzyme (soluble or immobilized) function. Such environments include prolonged exposure to high

- 6 -

temperature and extreme pH. Additionally, in organic solvents and aqueous-organic solvent mixtures, crosslinked enzyme crystals exhibit both stability and activity far beyond that of their soluble or conventionally-immobilized counterparts. Since so many biocatalysis processes depend on stability and activity of an enzyme under sub-optimal conditions, crosslinked enzyme crystals are advantageously used in industrial, clinical and research settings enzymes. Thus, crosslinked enzyme crystals represent an important advance in the area of biocatalysis, as attractive and broadly applicable catalysts for organic synthesis reactions [R.A. Persichetti et al., "Cross-Linked Enzyme Crystals (CLECs) of Thermolysin in the Synthesis of Peptides", J. Am. Chem. Soc., 117, pp. 2732-37 (1995) and J.J. Lalonde et al., J. Am. Chem. Soc., 117, pp. 6845-52 (1995)].

Despite the progress of protein catalysis technology in general, the need still exists for catalysts which have high activity in organic solvents.

DISCLOSURE OF THE INVENTION

The present invention provides crosslinked protein crystal formulations which exhibit high activity and productivity as catalysts in chemical reactions involving organic solvents or aqueous-organic solvent mixtures. Advantageously, this level of activity and productivity is greater than that of soluble or conventionally-immobilized proteins. This invention also provides methods for producing crosslinked protein crystal formulations and methods

- 7 -

using them to optimize chemical reactions in organic solvents, including those used in industrial scale biocatalysis.

According to one embodiment of this invention, crosslinked protein crystal formulations are produced by drying crosslinked protein crystals in the presence of a surfactant and an organic solvent. In a second embodiment of this invention, crosslinked protein crystal formulations are produced by lyophilizing crosslinked protein crystals in the presence of a surfactant and an organic solvent.

DETAILED DESCRIPTION OF THE INVENTION

In order that the invention herein described may be more fully understood, the following detailed description is set forth. In the description, the following terms are employed:

Organic Solvent -- any solvent of non-aqueous origin.

Aqueous-Organic Solvent Mixture -- a mixture comprising n% organic solvent, where n is between 1 and 99 and m% aqueous, where m is 100 - n.

Mixture Of Organic Solvents -- a combination of at least two different organic solvents in any proportion.

Crosslinked Protein Crystal Formulation -- a mixture of crosslinked protein crystals with one or more additional excipients, such as surfactants, salts, buffers, carbohydrates or polymers, in a dried, free-flowing powder or lyophilized form, rather than a slurry.

- 8 -

Catalytically Effective Amount -- an amount of a crosslinked protein crystal formulation of this invention which is effective to protect, repair, or detoxify the area to which it is applied over some
5 period of time.

Reactive Topical Composition -- a composition which is effective to protect, repair or detoxify the area to which it is applied over some period of time.

The crosslinked protein crystal formulations
10 of this invention are particularly advantageous because they retain high activity in harsh solvent environments that are typical of many industrial-scale chemical synthesis procedures. As a result of their crystalline nature, the crosslinked protein crystal components of
15 these formulations achieve uniformity across the entire crosslinked crystal volume. This uniformity is maintained by the intermolecular contacts and chemical crosslinks between the protein molecules constituting the crystal lattice, even when exchanged in organic or
20 mixed aqueous-organic solvents. Even in such solvents, the protein molecules maintain a uniform distance from each other, forming well-defined stable pores within the crosslinked protein crystal formulations that facilitate access of substrate to the catalyst, as well
25 as removal of product. In these crosslinked protein crystals, the lattice interactions, when fixed by chemical crosslinks, are particularly important in preventing denaturation, especially in organic solvents or mixed aqueous-organic solvents. Crosslinked protein
30 crystals and the constituent proteins within the

- 9 -

crystal lattice remain monodisperse in organic solvents, thus avoiding the problem of aggregation. These features of the crosslinked protein crystal components of crosslinked protein crystal formulations of this invention contribute to the high level of activity of those formulations in organic and aqueous-organic solvents.

In addition to their activity in organic solvents and aqueous-organic solvents, crosslinked protein crystal formulations according to this invention are particularly resistant to proteolysis, extremes of temperature and extremes of pH. The activity per crosslinked protein crystal unit volume is significantly higher than that of conventionally immobilized proteins or concentrated soluble proteins. This is because protein concentrations within the crosslinked protein crystal components of the formulations are close to theoretical limits.

By virtue of these advantages, the crosslinked protein crystal formulations of the present invention permit a major improvement in reaction efficiency. They provide improved yields under harsh conditions or situations requiring high throughput, enabling process chemists to concentrate on maximizing yield with less concern about reaction conditions.

The protein constituent of the crosslinked protein crystal formulations of this invention may be any protein including, for example, an enzyme or an antibody.

According to one embodiment of this invention, crosslinked protein crystal formulations are

- 10 -

characterized by activity in either an organic solvent or an aqueous-organic solvent mixture which is at least about 1.7 times greater than the activity of the equivalent amount of said protein in either crude form or pure form. In an alternate embodiment of this invention, the activity level of such formulations ranges between about 1.7 times and about 90 times greater than the activity of the equivalent amount of said protein in either crude form or pure form.

10 This invention also includes crosslinked protein crystal formulations characterized by a specific activity per milligram of solid in an organic solvent or an aqueous-organic solvent mixture which is at least about 4.3 times greater than that of said protein in either crude form or pure form. Crosslinked protein crystal formulations according to this invention may also be characterized by a specific activity per milligram of solid in an organic solvent or an aqueous-organic solvent mixture which is between about 4 times and about 442 times greater than that said protein in either crude form or pure form. And crosslinked protein crystal formulations of this invention may also be characterized by a specific activity per milligram of solid in an organic solvent or an aqueous-organic solvent mixture which has a level of activity greater than that of said protein in either crude form or pure form that is selected from the group consisting of at least about 50 times greater, at least about 100 times greater, at least about 200 times greater and at least about 300 times greater activity.

- 11 -

In another embodiment of this invention, crosslinked protein crystal formulations are characterized by activity in an organic solvent or an aqueous-organic solvent mixture which is at least 19
5 times greater than the activity of crosslinked protein crystals containing no surfactant. Crosslinked protein crystal formulations may also be characterized by activity in an organic solvent or an aqueous-organic solvent mixture which is between about 19 times and
10 about 100 times greater than the activity of crosslinked protein crystals containing no surfactant.

In all of the crosslinked protein formulations described above, the stated activity levels may be exhibited in either organic solvents, or
15 aqueous-organic solvents, or in both solvents. Such activity levels characterize all types of crosslinked protein crystal formulations, including crosslinked enzyme crystal formulations.

The crosslinked protein crystal formulations
20 of this invention may be used in any of a number of chemical processes. Such processes include industrial and research-scale processes, such as organic synthesis of specialty chemicals and pharmaceuticals, synthesis of intermediates for the production of such products,
25 chiral synthesis and resolution for optically pure pharmaceutical and specialty chemicals. Enzymatic conversion processes include oxidations, reductions, additions, hydrolyses, eliminations, rearrangements, esterifications and asymmetric conversions, including
30 stereoselective, stereospecific and regioselective reactions. Products which may be produced using these

- 12 -

reactions include chiral organic molecules, peptides, carbohydrates, lipids and other chemical species.

In carrying out any of the above-enumerated reactions, it will be understood by those of skill in the art that the organic solvent or aqueous-organic solvent chosen for the particular reaction should be one which is compatible with the protein constituent of the crosslinked protein crystal, as well as the surfactant used to stabilize the crosslinked protein crystal. Organic solvents may be selected from the group consisting of diols, polyols, polyethers, water soluble polymers and mixtures thereof. Examples of organic solvents include toluene, octane, tetrahydrofuran, acetone, and pyridine. Further examples include hydrophobic or polar organic solvents such as, water miscible or water immiscible solvents, diethylene glycol, 2-methyl-2,4-pentanediol, poly(ethylene glycol), triethylene glycol, 1,4-butanediol, 1,2-butanediol, 2,3-dimethyl-2,3-butanediol, 1,2-butanediol, dimethyl tartrate, monoalkyl ethers of poly(ethylene glycol), dialkyl ethers of poly(ethylene glycol), and polyvinylpyrrolidone, or mixtures thereof.

According to one embodiment, this invention includes methods for producing a selected product in an organic solvent or an aqueous-organic solvent mixture by combining at least one substrate and at least one protein which acts upon the substrate in the presence of an organic solvent or an aqueous-organic solvent mixture -- said protein being a crosslinked protein crystal formulation -- and maintaining the combination

- 13 -

under conditions which permit said protein to act upon the substrate, thereby producing the selected product. Products which may be produced in such methods include, for example, chiral organic molecules, peptides,
5 carbohydrates and lipids.

Crosslinked protein crystal formulations according to this invention may also be used in methods for purifying or separating a substance or molecule of interest from a sample, by virtue of the ability of the
10 formulation to bind to the substance or molecule of interest. Such separation methods comprise the steps of contacting the crosslinked crystal formulations with the substance or molecule of interest by any means, under conditions which permit said protein to bind with
15 said substance or molecule of interest in said sample to form a complex and separating said complex from said sample. In such methods, the crosslinked protein crystal formulations may be linked to a solid support, packed into a column or layered onto beads.

20 According to one embodiment of this invention, crosslinked protein crystal formulations may be used as a component of a biosensor for detecting an analyte of interest in a sample, for example, a fluid. Such a biosensor comprises (a) a crosslinked protein
25 crystal formulation, wherein said protein has the activity of acting on the analyte of interest or on a reactant in a reaction in which the analyte of interest participates; (b) a retaining means for said crosslinked protein crystal formulation, said retaining
30 means comprising a material which allows contact between said crosslinked protein crystal formulation

- 14 -

and a sample, said sample containing either (1) the analyte upon which the protein acts or (2) a reactant in a reaction in which the analyte participates; and, optionally, (c) a signal transducer which produces a
5 signal in the presence or absence of the analyte. The means for detecting the activity of the protein on the analyte or reactant may be selected from the group consisting of pH electrodes, light sensing devices, heat sensing devices and means for detecting electrical
10 charges. The signal transducer may be selected from the group consisting of optical transducers, electrical transducers, electromagnetic transducers and chemical transducers.

In an alternate embodiment of this invention,
15 crosslinked protein crystal formulations may be used in extracorporeal devices for altering a component of a sample, or for selective degradation or removal of a component of a sample, such as a fluid sample. Such extracorporeal devices comprise (a) a crosslinked
20 protein crystal formulation, wherein the protein has the activity of acting on the component or a reactant in a reaction in which the component participates and (b) a retaining means for said crosslinked protein crystal formulation, said retaining means comprising a
25 material which allows contact between said crosslinked protein crystal formulation and a sample, said sample containing either (1) the component upon which said protein acts or (2) a reactant in a reaction in which the component participates. In such extracorporeal
30 devices, the retaining means may comprise a porous material on which said crosslinked protein crystal

- 15 -

formulation is retained or a tube in which said crosslinked protein crystal formulation is present.

Thus, crosslinked protein crystal formulations according to this invention may be advantageously used instead of conventional soluble or immobilized proteins in biosensors and extracorporeal devices. Such uses of the crosslinked protein crystal formulations of this invention provides biosensors and extracorporeal devices characterized by higher degrees of sensitivity, volumetric productivity and throughput than those of biosensors and extracorporeal devices based on conventional soluble or immobilized proteins.

Alternatively, crosslinked protein crystal formulations according to this invention may be used in chromatographic techniques. Such techniques include size exclusion chromatography, affinity chromatography and chiral chromatography. Chromatography of a sample may be carried out in the presence of an organic solvent or an aqueous-organic solvent mixture by contacting said sample with a crosslinked protein crystal formulation under conditions which permit the components of said sample to bind with said protein to form a complex and collecting said components as separate fractions. The crosslinked protein crystal formulation may be contained in a packed chromatography column.

According to another embodiment of this invention, crosslinked crystal protein formulations may be used in gas phase reactors, such as catalytic convertors for gas phase reactions. For example, gas may be passed through a column packed with a

- 16 -

crosslinked protein formulation -- which degrades the gas.

Crosslinked protein crystal formulations according to this invention may also be used in various environmental applications. They may be used in place of conventional soluble or immobilized proteins for environmental purposes, such as cleaning-up oil slicks. For example, one or more organic solvents may be added to the oil slick, followed by a crosslinked protein crystal formulation.

Crosslinked protein crystal formulations according to the present invention may also be used for air purification in conjunction with air filtration. For example, air may be passed through a column packed with a crosslinked protein formulation to degrade and filter out any unwanted contaminants.

This invention also includes methods for increasing the activity of crosslinked protein crystals in an organic solvent or an aqueous-organic solvent mixture comprising the steps of combining the crosslinked protein crystals with a surfactant to produce a combination and drying the combination of crosslinked protein crystals and surfactant in the presence of an organic solvent to form a crosslinked protein crystal formulation.

Alternatively, crosslinked protein crystal formulations according to this invention may be used as ingredients in topical creams and lotions, for skin protection or detoxification. They may also be used as anti-oxidants in cosmetics.

- 17 -

According to this invention, any individual, including humans and other mammals, may be treated in a pharmaceutically acceptable manner with a catalytically effective amount of a crosslinked protein crystal
5 formulation for a period of time sufficient to protect, repair or detoxify the area to which it is applied. For example, crosslinked protein crystal formulations may be topically administered to any epithelial surface. Such epithelial surfaces include oral,
10 ocular, aural, nasal surfaces.

The crosslinked protein crystal formulations may be in a variety of conventional depot forms employed for topical administration to provide reactive topical compositions. These include, for example,
15 semi-solid and liquid dosage forms, such as liquid solutions or suspensions, gels, creams, emulsions, lotions, slurries, powders, sprays, foams, pastes, ointments, salves, balms and drops. Compositions comprising crosslinked protein crystal formulations may
20 also comprise any conventional pharmaceutically acceptable carrier or adjuvant. These carriers and adjuvants include, for example, ion exchangers, alumina, aluminum stearate, lecithin, buffer substances, such as phosphates, glycine, sorbic acid,
25 potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium, trisilicate, cellulose-
30 based substances and polyethylene glycol. Adjuvants for topical or gel base forms may include, for example,

- 18 -

sodium carboxymethylcellulose, polyacrylates, polyoxyethylele-polyoxypropylene-block polymers, polyethylene glycol and wood wax alcohols.

Alternatively, crosslinked protein crystal
5 formulations may be formulated into a health care device selected from the group consisting of dressings, sponges, strips, plasters, bandages, patches or gloves.

The most effective mode of administration and dosage regimen will depend upon the effect desired,
10 previous therapy, if any, the individual's health status and response to the crosslinked protein crystal formulation and the judgment of the treating physician. The crosslinked protein crystal formulation may be administered in any pharmaceutically acceptable topical
15 dosage form, at one time or over a series of treatments.

The amount of the crosslinked protein crystal formulation that may be combined with carrier materials to produce a single dosage form will vary depending
20 upon the particular mode of topical administration, formulation, dose level or dose frequency. A typical preparation will contain between about 0.1% and about 99%, preferably between about 1% and about 10%, crosslinked protein crystal formulation (w/w).

25 Upon improvement of the individual's condition, a maintenance dose of crosslinked protein crystal formulation may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced as a function
30 of the symptoms, to a level at which the improved condition is retained. When the symptoms have been

- 19 -

alleviated to the desired level, treatment should cease. Individuals may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.

5 According to the present invention, preparation of crosslinked protein crystal formulations includes the steps of crystallizing and crosslinking the protein, which may be carried out as described in PCT patent application WO92/02617, which is
10 incorporated herein by reference. Alternatively, crosslinked protein crystal formulations may be prepared as illustrated below for crosslinked enzyme crystal formulations.

Preparation of Crosslinked Enzyme Crystal

15 Formulations - Enzyme Crystallization

Enzyme crystals are grown by the controlled precipitation of enzyme out of aqueous solution or aqueous solution-containing organic solvents. Conditions to be controlled include, for example, the
20 rate of evaporation of solvent, the presence of appropriate co-solutes and buffers, pH and temperature. A comprehensive review of the various factors affecting the crystallization of proteins has been published by McPherson, Methods Enzymol., 114, pp. 112-20 (1985).

25 McPherson and Gilliland, J. Crystal Growth, 90, pp. 51-59 (1988) have compiled comprehensive lists of proteins and nucleic acids that have been crystallized, as well as the conditions under which they were crystallized. A compendium of crystals and
30 crystallization recipes, as well as a repository of

- 20 -

- coordinates of solved protein and nucleic acid crystal structures, is maintained by the Protein Data Bank at the Brookhaven National Laboratory [Bernstein et al., J. Mol. Biol., 112, pp. 535-42 (1977)]. These
- 5 references can be used to determine the conditions necessary for crystallization of an enzyme previously crystallized, as a prelude to the formation of an appropriate crosslinked enzyme crystal, and can guide the crystallization strategy for other enzymes.
- 10 Alternatively, an intelligent trial and error search strategy can, in most instances, produce suitable crystallization conditions for many enzymes, provided that an acceptable level of purity can be achieved for them [see e.g., C.W. Carter, Jr. and C.W. Carter,
- 15 J. Biol. Chem., 254, pp. 12219-23 (1979)].

Enzymes which may be crystallized to form the crosslinked enzyme crystal component of the formulations according to this invention include hydrolases, isomerases, lyases, ligases, transferases

20 and oxidoreductases. Examples of hydrolases include thermolysin, elastase, esterase, lipase, nitrilase, hydantoinase, asparaginase, urease, subtilisin and other proteases and lysozyme. Examples of lyases include aldolases and hydroxynitril lyase. Examples of

25 oxidoreductases include glucose oxidase, alcohol dehydrogenase and other dehydrogenases.

For use in crosslinked enzyme crystal formulations according to this invention, the large single crystals which are needed for X-ray diffraction

30 analysis are not required. Microcrystalline showers are suitable.

- 21 -

In general, crystals are produced by combining the enzyme to be crystallized with an appropriate aqueous solvent or aqueous solvent containing appropriate precipitating agents, such as salts or organics. The solvent is combined with the protein at a temperature determined experimentally to be appropriate for the induction of crystallization and acceptable for the maintenance of enzyme activity and stability. The solvent can optionally include co-solutes, such as divalent cations, co-factors or chaotropes, as well as buffer species to control pH. The need for co-solutes and their concentrations are determined experimentally to facilitate crystallization. In an industrial scale process, the controlled precipitation leading to crystallization can best be carried out by the simple combination of protein, precipitant, co-solutes and, optionally, buffers in a batch process. Alternative laboratory crystallization methods, such as dialysis or vapor diffusion can also be adapted. McPherson, supra, and Gilliland, supra, include a comprehensive list of suitable conditions in their reviews of the crystallization literature. Occasionally, incompatibility between the crosslinking reagent and the crystallization medium might require exchanging the crystals into a more suitable solvent system.

Many of the enzymes for which crystallization conditions have already been described, have considerable potential as practical catalysts in industrial and laboratory chemical processes and may be used to prepare crosslinked enzyme crystal formulations

- 22 -

according to this invention. It should be noted, however, that the conditions reported in most of the above-cited references have been optimized to yield, in most instances, a few large, diffraction quality
5 crystals. Accordingly, it will be appreciated by those of skill in the art that some degree of adjustment of these conditions to provide a high yielding process for the large scale production of the smaller crystals used in making crosslinked enzyme crystals may be necessary.

10 Preparation of Crosslinked Enzyme Crystal
Formulations - Crosslinking of Enzyme Crystals

Once enzyme crystals have been grown in a suitable medium they can be crosslinked. Crosslinking results in stabilization of the crystal lattice by
15 introducing covalent links between the constituent enzyme molecules of the crystal. This makes possible the transfer of enzyme into an alternate reaction environment that might otherwise be incompatible with the existence of the crystal lattice or even with the
20 existence of intact protein. Crosslinking can be achieved by a wide variety of multifunctional reagents, including bifunctional reagents. According to a preferred embodiment of this invention, the crosslinking agent is glutaraldehyde. For a
25 representative listing of other available crosslinking reagents see, for example, the 1990 catalog of the Pierce Chemical Company.

Crosslinking with glutaraldehyde forms strong covalent bonds primarily between lysine amino acid
30 residues within and between the enzyme molecules in the

- 23 -

crystal lattice. The crosslinking interactions prevent the constituent enzyme molecules in the crystal from going back into solution, effectively insolubilizing or immobilizing the enzyme molecules into microcrystalline particles (preferably having lengths which are, on average, less than or equal to 10^{-1} mm).

Preparation of Crosslinked Enzyme
Crystal Formulations - Exposure of
Crosslinked Enzyme Crystals to Surfactants

10 Crosslinked enzyme crystals prepared as described above, may be used to prepare enzyme crystal formulations for reactions in organic solvents and aqueous-organic solvent mixtures by being contacted with a surfactant. After exposure of the crosslinked
15 enzyme crystals to the surfactant and subsequent drying in the presence of an organic solvent, the resulting crosslinked enzyme crystal formulation is particularly active and stable in organic solvents and aqueous-organic solvent mixtures. The details described below
20 with respect to crosslinked enzyme crystal formulations and their production are equally applicable to crosslinked protein crystal formulations.

Surfactants useful to prepare crosslinked enzyme crystal formulations according to this invention
25 include cationic, anionic, non-ionic or amphoteric, or mixtures thereof. The preferred surfactant will depend upon the particular enzyme component of the crosslinked enzyme crystals to be used to prepare the crosslinked enzyme crystal formulation. This may be determined by
30 carrying out a routine screening procedure based on a

- 24 -

reaction catalyzed by the particular enzyme. Such screening procedures are well known to those of skill in the art. Illustrative screening processes are set forth in Examples 6-8.

- 5 Examples of useful cationic surfactants include amines, amine salts, sulfonium, phosphonium and quarternary ammonium compounds. Specific examples of such cationic surfactants include:

 Methyl trioctylammonium chloride (Aliquat
10 336)

 N,N',N'-polyoxyethylene(10)-N-tallow-1,3-diaminopropane

 (EDT-20, ' PEG-10 tallow).

- Useful anionic surfactants include, for
15 example, linear alkylbenzene sulphonate, alpha-olefin sulphonate, alkyl sulphate, alcohol ethoxy sulfate, carboxylic acids, sulfuric esters and alkane sulfonic acids. Examples of anionic surfactants include:

 Triton QS-30 (Anionic)
20 Aerosol 22
 dioctyl sulfosuccinate (AOT)
 Alkyl Sodium Sulfate (Niaproof):
 Type-4
 Type-8
25 Alkyl (C9-C13) Sodium Sulfates
 (TEEPOL HB7).

- Non-ionic surfactants useful for
stabilization include nonyl phenol ethoxylate, alcohol
ethoxylate, sorbitan trioleate, non-ionic block
30 copolymer surfactants, polyethylene oxide or
polyethylene oxide derivatives of phenol alcohols or

- 25 -

fatty acids. Examples of non-ionic surfactants include:

Polyoxyethylene Ethers:

4 lauryl Ether (Brij 30)

5 23 lauryl Ether (Brij 35)

Octyl Phenoxy polyethoxyethanol (Tritons):

Tx-15

Tx-100

Tx-114

10 Tx-405

DF-16

N-57

DF-12

CF-10

15 CF-54

Polyoxyethylenesorbitan:

Monolaurate (Tween 20)

Sorbitan:

Sesquioleate (Arlacel 83)

20 Trioleate (Span 85)

Polyglycol Ether (Tergitol):

Type NP-4

Type NP-9

Type NP-35

25 Type TMN-10

Type 15-S-3

Type TMN-6(2,6,8, Trimethyl-4-nonyloxypolyethoxyethanol

Type 15-S-40.

- 26 -

Generally, in order to prepare crosslinked enzyme crystal formulations, the surfactant should be added to a crosslinked enzyme crystal-containing solution in an amount sufficient to allow the

5 surfactant to equilibrate with and/or penetrate the crosslinked enzyme crystals. Such an amount is one which provides a weight ratio of crosslinked enzyme crystals to surfactant between about 1:1 and about 1:5, preferably between about 1:1 and about 1:2. The

10 crosslinked enzyme crystals are contacted with surfactant for a period of time between about 5 minutes and about 24 hours, preferably between about 30 minutes and about 24 hours. Following that contact, the crosslinked enzyme crystal/surfactant combination may

15 be dried in the presence of an organic solvent to form the crosslinked enzyme crystal formulation.

The choice of organic solvent and length of drying time will depend on the particular crosslinked enzyme crystals and the particular surfactant used to

20 produce the crosslinked enzyme crystal formulations. Nevertheless, the solvent and drying time should be those which provide a crosslinked enzyme crystal formulation characterized by a water content that permits the formulation to have maximum activity and

25 stability in organic solvents or aqueous-organic solvent mixtures. According to one embodiment of this invention, the drying time may be between about 5 minutes and about 24 hours, preferably between about 30 minutes and about 24 hours. The organic solvent used

30 in the drying step may be present in an amount between about 10 wt% and about 90 wt% of the total mixture,

- 27 -

preferably between about 40 wt% and about 80 wt% of the total mixture.

Alternatively, the crosslinked enzyme crystal/surfactant combination may be lyophilized in the presence of an organic solvent. Lyophilization may be carried out for a period of time between about 30 minutes and about 18 hours.

The resulting crosslinked enzyme crystal formulation should contain between about 10 wt% and about 70 wt% of surfactant, by weight of the final formulation, preferably between about 25 wt% and about 45 wt% of surfactant, by weight of the final formulation.

In order that this invention may be better understood, the following examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any matter.

EXAMPLES

20 Example 1 - Preparation of A Crosslinked LPS Crystal Formulation

A slurry of 15 kg crude Pseudomonas cepacia lipase (PS 30 lipase - Amano) ("LPS") was dissolved in 100 L distilled deionized water and the volume brought to 200 L with additional distilled deionized water. The suspension was mixed in an Air Drive Lightning mixer for 2 hours at room temperature and then filtered through a 0.5 μ filter to remove celite. The mixture was then ultrafiltered and concentrated to 10 L (121.4

- 28 -

g) using a 3K hollow fiber filter membrane cartridge. Solid calcium acetate was added to a concentration of 20 mM $\text{Ca}(\text{CH}_3\text{COO})_2$. The pH was adjusted to 5.5 with concentrated acetic acid, as necessary. The mixture
5 was heated to and maintained at a temperature of 30°C. Magnesium sulfate was added to a 0.2 M concentration followed by glucopon to a 1% concentration. Isopropanol was then added to a final concentration of 23%. The resulting solution was mixed for 30 minutes
10 at 30°C, then cooled from 30°C to 12°C over a 2 hour period. Crystallization was then allowed to proceed for 16 hours.

The crystals were allowed to settle and soluble protein was removed using a peristaltic pump
15 with tygon tubing having a 10 ml pipette at its end. Fresh crystallization solution (23% isopropyl alcohol, 0.2 M MgSO_4 , 1% glucopon, 20 mM $\text{Ca}(\text{CH}_3\text{COO})_2$, pH 5.5) was added to bring the concentration of protein to 30 mg/ml (O.D. 280 of a 1 mg/ml solution = 1.0, measured using a
20 spectrophotometer at wavelength 280). The crystal yield was about 120 grams. The crystal solution was then crosslinked as follows.

A 2 liter aliquot of crosslinking agent was prepared by mixing 1 volume of 50% glutaraldehyde with
25 4 volumes of 0.1 M Tris (pH 9.25). Crosslinking was then carried out using 13.5 ml crosslinking agent per gram of enzyme. More particularly, a 0.4 ml aliquot of the crosslinking agent was then added to 1 ml of enzyme slurry (30 mg/ml), over a total addition time of 2
30 hours. The mixture was allowed to stand for 8 hours at room temperature for crosslinking. The crosslinking

- 29 -

reaction was stopped by washing the crosslinked crystals extensively in a filter press with an approximately 1.5 crystal slurry volume of buffer (10 mM Tris, 10 mM CaCl_2 , pH 7.0).

5 A 30 gram aliquot of the above-prepared crosslinked LPS enzyme crystals was suspended in 340 ml storage buffer (10 mM Tris, 10 mM CaCl_2 , pH 7.0) and the mixture poured into a sintered glass funnel (porosity ~10-20 μ) at room temperature. The enzyme crystals
10 were exposed to the surfactant EDT-20; PEG-10 tallow aminopropylamine as described below. This surfactant was selected by the screening process set forth in Example 6, *infra*.

 The buffer above the crosslinked LPS crystals
15 was filtered in a sintered glass funnel (described above), keeping the enzyme crystals wet throughout the process. The height of the crosslinked enzyme crystals in the funnel was measured and found to be 60 ml. The surfactant N, N', N-polyoxyethylene (10)-N-tallow-1,3 -
20 diaminopropane (EDT-20', PEG-10 tallow) was added together with the solvent 2-butanone, such that the ratio of surfactant:crosslinked enzyme crystals was 1:1 (30 g surfactant:30 g LPS = 30 ml). This was done by pouring a mixture of 30 ml 2-butanone and 30 ml
25 surfactant, for a total of 60 ml, on top of the crosslinked enzyme crystals. A gentle suction was applied to ensure that the crosslinked enzyme crystals were coated with the surfactant and so that the enzyme cake did not dry. After 30 minutes at room
30 temperature, the mixture was then transferred to a drying vessel (a fritted pressure filter funnel) in a

- 30 -

stream of air to a water content of about 1-3%, as determined by Karl Fisher titration.

LPS crosslinked crystal formulations according to this invention may also be prepared using crosslinked LPS crystals sold under the trade name ChiroCLEC-PC, which are available from Altus Biologics, Inc. (Cambridge, Massachusetts).

Example 2 - Preparation of A
Crosslinked CRL Crystal Formulation

10 A 5 kg aliquot of Candida rugosa lipase ("CRL") in powder form (Amano) was mixed with 5 kg celite and dissolved in 102 L distilled deionized water and the volume brought to 200 L with distilled deionized water. The suspension was mixed in an Air
15 · Drive Lightning mixer for 2 hours at room temperature and then filtered through a 0.5 micron filter to remove celite. The mixture was then ultrafiltered and concentrated to 14 L (469 g) using a 3K hollow fiber filter membrane cartridge. Solid calcium acetate was
20 added to a concentration of 5 mM $\text{Ca}(\text{CH}_3\text{COO})_2$. The pH was adjusted to 4.8 with concentrated acetic acid, as necessary. The mixture was heated to and maintained at a temperature of 25°C. A 3.5 L aliquot of (100%) 2-methyl-2,4-pentanediol "MPD" and crystal seeds (0.5 g
25 protein) were added. The resulting solution was mixed overnight. Crystallization was then allowed to proceed overnight, for about 17-20 hours.

The crystals were allowed to settle and soluble protein was removed using a peristaltic pump

- 31 -

with tygon tubing having a 10 ml pipette at its end. Fresh crystallization solution (20% MPD, 5 mM $\text{Ca}(\text{CH}_3\text{COO})_2$, pH 4.8) was added to bring the concentration of protein to 35 mg/ml (O.D. 280 of a 1 mg/ml solution = 1.0). This step was then repeated. The crystal yield was about 217 grams. The crystal solution was then crosslinked as follows.

Crosslinking agent was prepared by mixing 1 volume of 50% glutaraldehyde with 1 volume of 0.3 M sodium borate buffer (pH 9.0) and heating the mixture for 1 hour at 60°C. The mixture was then allowed to stand until it cooled to room temperature, with the pH being adjusted to 6.0, as necessary, using HCl. Crosslinking was carried out using 3.885 ml (1.949 g) of crosslinking agent, per gram of enzyme. More particularly, a 1686 ml aliquot of the crosslinking agent was then added to 217 g of enzyme slurry by pumping the crosslinking agent slowly, for a total addition time of 2 hours. The mixture was then let stand at room temperature for an additional 16 hours for crosslinking. The crosslinking reaction was stopped by washing the crosslinked crystals extensively in a Buchner funnel with a 1 μ filter, first with 30 L water then with 2 M sodium chloride and buffer (10 mM Tris, 10 mM CaCl_2 , pH 7.0).

A 6 gram aliquot of the above-prepared crosslinked CRL enzyme crystals was suspended in 100 ml storage buffer (10 mM Tris, 10 mM CaCl_2 , pH 7.0) and the mixture poured into a sintered glass funnel (porosity ~10-20 μ) at room temperature. The buffer was then removed from the enzyme. The enzyme crystals were

- 32 -

exposed to the surfactant tergitol type TMN-6 as described below. This surfactant was selected by the screening process set forth in Example 8, *infra*.

The buffer above the crosslinked CRL crystals
5 was filtered in a sintered glass funnel (as described above), keeping the crosslinked enzyme crystals wet throughout the process. The height of the crosslinked enzyme crystals in the funnel was measured and found to be 34 ml. The surfactant was added together with the
10 solvent 2-butanone, such that the ratio of surfactant:crosslinked enzyme crystals was 1:1 (6 g CRL:6 g surfactant = 5.7 ml). This was done by pouring a mixture of 28.3 ml 2-butanone and 5.7 ml surfactant, for a total of 34 ml, on top of the crosslinked enzyme
15 crystals. A gentle suction was applied to ensure that the crosslinked enzyme crystals were coated with the surfactant and so that the enzyme cake did not dry. After 30 minutes at room temperature, the mixture was then transferred to a drying vessel (a fritted pressure
20 filter funnel) in a stream of air to a water content of about 7-13%, as determined by Karl Fisher titration.

CRL crosslinked crystal formulations according to this invention may also be prepared using crosslinked CRL crystals sold under the trade name
25 ChiroCLEC-CR, which are available from Altus Biologics, Inc. (Cambridge, Massachusetts).

Example 3 - Preparation of A Crosslinked ABL Crystal Formulation

- 33 -

A slurry of 30 kg or 25 L of Bacillus licheniformis subtilisin A ("ABL") (Alcalase) was mixed in an Air Drive Lightning mixer with 50 L of 15% Na₂SO₄ (pH 5.5). Crystal seeds (0.27 g protein) were added,
5 and the mixture maintained at a temperature of 30°C. Crystallization was then allowed to proceed for a period of 3-4 days. The mother liquor was removed using a Buchner funnel with a 1 μ filter.

The crystals were washed with 50 L of 15%
10 Na₂SO₄ (pH 5.5) and then suspended in 40 L of 15% Na₂SO₄ (pH 5.5). The crystal yield was about 1069 grams. The crystal solution was then crosslinked as follows.

Crosslinking was carried out using 1.68 ml of 50% glutaraldehyde crosslinking agent per gram of
15 enzyme. More particularly, a 1796 ml aliquot of crosslinking agent was added to 1069 g enzyme over a total addition time of 30 minutes to 1 hour. The mixture was allowed to mix for 4 hours at room temperature for crosslinking, keeping the pH at 5.5 at
20 all times. The crosslinking reaction was stopped by washing the crosslinked crystals extensively in a filter press with water until the conductivity of washing was 2 ms/cm. Then the crosslinked enzyme crystals were suspended in buffer (0.1 NaAc, 20 mM
25 CaCl₂, pH 5.7).

A 20 gram aliquot of the above-prepared crosslinked ABL enzyme crystals was suspended in 100 ml storage buffer (0.1 NaAc, 20 mM CaCl₂, pH 5.7) and the mixture poured into a sintered glass funnel (porosity
30 ~10-20 μ) at room temperature. The enzyme crystals were exposed to the surfactant tergitol type 15-S-3 as

- 34 -

described below. This surfactant was selected by the screening process set forth in Example 7, *infra*.

The buffer above the crosslinked ABL crystals was filtered in a sintered glass funnel (as described
5 above), keeping the crosslinked enzyme crystals wet throughout the process. The height of the crosslinked enzyme crystals in the funnel was measured and found to be 50 ml. The surfactant was added together with the solvent isopropanol, such that the ratio of
10 surfactant:crosslinked enzyme crystals was 1:1.5 (30 g ABL:30 ml surfactant = 50 ml). This was done by pouring a mixture of 20 ml isopropanol and 30 ml surfactant, for a total of 50 ml, on top of the crosslinked enzyme crystals. A gentle suction was
15 applied to ensure that the crosslinked enzyme crystals were coated with the surfactant and so that the enzyme cake did not dry. After 30 minutes at room temperature, the mixture was then transferred to a drying vessel (a fritted pressure filter funnel) in a
20 stream of air to a water content of about 1-4%, as determined by Karl Fisher titration.

Alternatively, 15 g of wet cake of ABL crosslinked enzyme crystals may be mixed with 20 g surfactant and 30 ml isopropanol. The mixture may then
25 be incubated for 30 minutes. Subsequently, solvent and surfactant may be removed by suction, as described above. The wet crosslinked enzyme crystals may then be transferred to a lyophilization vessel and frozen in acetone in dry ice for 30 minutes. Then, the
30 lyophilization vessel is transferred to the lyophilizer and let go for 30 minutes.

- 35 -

Lyophilized crosslinked enzyme crystal formulations prepared as described above may be stored at room temperature or at 4°C, prior to their use in organic solvents. Lyophilized crosslinked enzyme crystal formulations may be stored at room temperature.

ABL crosslinked crystal formulations according to this invention may also be prepared using crosslinked ABL crystals sold under the trade name ChiroCLEC-BL, which are available from Altus Biologics, Inc. (Cambridge, Massachusetts).

Example 4 - Activity of Crosslinked
Enzyme Crystal Formulations in Organic Solvents

The activities of the crosslinked enzyme crystal formulations, as prepared above, or their crude enzyme counterparts, in the resolution of alcohols, acids and amines are presented in Table 1. Enzyme activity was assayed by HPLC and gas chromatography ("GC"). The particular resolutions generating the data in Table 1 were carried out as described below.

Resolution of (+/-) Menthol by Transesterification

A solution of (+/-) Menthol (449 mM) in 1 ml of toluene containing 7.5 μ l (0.15%) H₂O was stirred with 4 mg of the crosslinked CRL crystal formulation prepared in Example 2 for 5 minutes, until a fine suspension was attained. Vinyl acetate (449 mM) was added and the resulting suspension was stirred at 25°C for 4 hours, at which time capillary gas chromatography

- 36 -

("GC") analysis indicated 15% conversion. The GC conditions were as follows: DB1701 15 m x 0.25 mm GC Column, 25 mm film thickness (J & W Scientific, Folsom CA); helium flow at 25 cm/sec; Temperature program:

5 Initial = 119°C for 1 minute, Gradient₁ rate = 5°C/min to 130°C for 0.3 minutes, Gradient₂ rate = 70°C/min to 175°C for 1.86 minute. Retention times: 2.85 minutes [(+) Menthol], 4.77 minutes [ester]. The reaction was halted by suction filtration of the catalyst. The

10 optical purity of the product ester was determined to be 99.4% enantiomeric excess ("ee") by GC analysis.

The chiral GC conditions were as follows: Cyclodex B 25 m capillary GC Column, 25 mm i.d. (J & W Scientific, Folsom CA); N₂ flow at 1 ml/min; Temperature

15 program: Initial = 90°C for 5 min, Gradient rate = 1°C/min, Final = 115°C for 10 minutes. Retention times: 24.90 minutes [(+) Menthol], 25.40 minutes [(-) Menthol], 35.97 minutes [(-) ester], 36.11 minutes [(+) ester].

20 Esterification of Ibuprofen with n-Amyl Alcohol

(R,S)-Ibuprofen (97 mM) was dissolved in 1 ml of isooctane. To this solution was added 460 mM of n-amyl alcohol and 1 mg of the crosslinked CRL crystal formulation prepared in Example 2. The suspension was

25 stirred at room temperature and the production of n-amyl Ibuprofen was followed by chiral HPLC. After 24 hours, the conversion had reached 28%.

The chiral HPLC conditions were as follows:
Acid: (R,R) Whelk-O1, (Regis Technologies, Morton

- 37 -

Grove, IL) 5 mm, 100 Å, 25 cm column. Mobile phase = hexane 0.5% acetic acid. Over a 30 minute period, hexane without acetic acid was substituted (at an even rate) for the acidified hexane. Helium flow rate = 1 ml/min., UV detection at 254 nm. Retention times: 16.7 and 19.2 minutes for the ester, 21.8 and 28.1 minutes for the acid.

Resolution of (R,S)-2-Hydroxyhexanoic Acid by Esterification

10 To a solution of (R,S) 2-hydroxyhexanoic acid (532 mM) in 1 ml of toluene containing n-BuOH (1060 mM) was added 10 mg of the crosslinked CRL crystal formulation prepared in Example 2. The resulting mixture was magnetically stirred at 25°C for 1 hour, at which time capillary GC analysis indicated 46% conversion. The GC conditions were as follows: DB1701 15 m x 0.25 mm GC Column, 25 mm film thickness (J & W Scientific, Folsom CA); helium flow at 25 cm/sec; Temperature program: Initial = 110°C for 5 minutes, Gradient rate = 20°C/min to 200°C. Sample preparation: 10 µl of reaction mixture in 1 ml hexane with 100 µl MeOH and 100 µl TMS-diazomethane-2M in hexane. Retention times: 2.12 minutes [methyl ester], 6.46 minutes [butyl ester]. The reaction was halted by suction filtration of the catalyst. Optical purity of the butyl ester and the acid (as its methyl ester) were determined by chiral GC analysis.

The chiral GC conditions were as follows:
Cyclodex B 25 m capillary GC Column, 25 mm i.d. (J & W

- 38 -

Scientific, Folsom CA); N₂ flow at 1 ml/min; Temperature program: Initial = 80° C for 30 minutes, Gradient rate = 5°C/min, Final = 170° C for 10 minutes. Retention times: 27.80 minutes [R-methyl ester], 31.03 minutes
5 [S-methyl ester], 44.30 minutes [R-butyl ester] and 44.50 minutes [S-butyl ester].

Resolution of Phenethyl Alcohol by Transesterification

To 200 mM phenethyl alcohol and 200 mM vinyl acetate in 1 ml toluene was added 1.2 mg of the
10 crosslinked LPS crystal formulation prepared in Example 1 and the reaction mixture stirred at room temperature for 30 minutes. The catalyst was removed by centrifugation to stop the reaction. Conversion and optical purity were determined by chiral GC.

15 The chiral GC conditions were as follows:
Cyclodex capillary GC 25 m column, 25 mm i.d. (J & W Scientific, Folsom, CA) N₂ flow at 1 ml/min.
Temperature program: Initial 100°C for 4 minutes, Gradient rate 5°C/min., to 135°C and 2 minutes at 135°C,
20 2°C/min to 144°C and 5 minutes at 144°C, 5°C/min to 150°C and 2 minutes at 150°C. Retention times: 12.08 and 12.47 for (S) and (R) ester, respectively; 12.25 and 12.55 min for (R) and (S) alcohol, respectively.
Conversion was found to be 41.7% and the ee of product
25 and substrate in this conversion was found to be 98.5% and 70.42%, respectively, with an E value of 297. E was calculated according to C.S. Chen et al., J. Am. Chem. Soc., 104, pp. 7294-99 (1982). See J.J. Lalonde et al., J. Am. Chem. Soc., 117, pp. 6845-52 (1995) for

- 39 -

a discussion of the applicability of E for reactions affected by inhibition or catalyzed by crude enzymes.

Resolution of (+)-Sulcatol

To a solution of 80 mM (+)-Sulcatol and 120
5 mM vinyl acetate in 1 ml of toluene was added 4 mg of
the crosslinked LPS crystal formulation prepared in
Example 1. The mixture was stirred at room temperature
for 20 hours. The catalyst was then removed by
filtration. The optical purity of product and
10 remaining starting material were directly analyzed by
GC using a chiral GC column. The ee of the remaining
starting material and product alcohol was >98% and
51.3%, respectively.

The chiral GC conditions were as follows:
15 Cyclodex B capillary GC 25 m column, 25 mm i.d. (J & W
Scientific, Folsom, CA), helium flow at 1 ml/min.
Temperature program: Initial: 90°C for 10 minutes,
Gradient rate: 5°C per minute, Final 130° C for 20
minutes. Retention time: (S)-sulcatol, 12.50 minutes;
20 (R)-sulcatol, 12.32 minutes; (S)-sulcatol acetate,
14.43 minutes; (R)-sulcatol acetate, 15.12 minutes.
The conversion was 66.1%. The E value was calculated
to be 27.

Resolution of (+)-2-Octanol

25 To a solution of 80 mM (+)-2-octanol and 120
mm vinyl acetate in 1 ml of toluene was added 4 mg of
the crosslinked LPS crystal formulation prepared in

- 40 -

Example 1. The mixture was stirred at room temperature for 4 hours. The catalyst was then removed by filtration. The optical purity of the acetate product was directly analyzed by GC using a chiral GC column.

- 5 The ee was determined to be 63.0%. The remaining alcohol was converted to its corresponding butyrate by reaction with butyric anhydride in pyridine. The optical purity of the butyrate derivative was then analyzed with GC. The ee was 83.7%.

- 10 The chiral GC conditions were as follows:
Cyclodex B capillary GC 25 m column, 25 μ m i.d. (J & W Scientific, Folsom, CA), helium flow at 1 ml/min.
Temperature program: Initial = 90°C for 10 minutes,
Gradient rate 2°C per minute. Final 130°C for 20
15 minutes. Retention time: (S)-2-octanol acetate, 15.66 minutes; (R)-2-octanol acetate, 16.93 minutes; (S)-2-octanol butyrate, 26.49 minutes; (R)-2-octanol butyrate, 26.95 minutes. The conversion was 57.1%.
The E value was calculated to be 9.8.

20 Resolution of Tryptamine

- A solution of 200 mM tryptamine and 400 mM 2,2,2-trifluoroethyl butanoate in 1 ml of tert-butanol was incubated with 16 mg of the crosslinked ABL crystal formulation prepared in Example 3 on a rotary shaker at
25 40°C. When the desired level of conversion was reached, the catalyst was removed by centrifugation and washed with ethyl acetate. The combined organic mixtures were evaporated in vacuo to give a residue which was then purified by silica gel column

- 41 -

chromatography to give the remaining tryptamine and the butyl amide product. The optical purity of the butyl amide product was directly analyzed by chiral HPLC. The remaining amine was converted to its urethane derivative by treatment with methyl chloroformate and analyzed for optical purity by chiral HPLC: ee = 94% at 20% conversion; R-alphamethyltryptamine; ee > 98% at 53% conversion.

The chiral HPLC conditions were as follows:

10 Chiracel OJ 25 cm column (Chiral Technologies, Exton, PA, a division of Daicel Chemical Inc.), for butyl amide; mobile phase = 80% hexane (with 0.1% TFA), 20% isopropanol (with 0.1% TFA), helium flow rate = 1 ml/min., UV detection at 254 nm. Retention times: D- butyl amide product, 9.3 minutes and L-butyl amide product, 11.2 minutes. D-urethane derivative, 24.8 minutes and L-urethane derivative, 27.6 minutes.

Each of the resolutions described above, was carried out with the crude enzyme counterpart to the crosslinked enzyme crystal formulation, using the enzyme concentrations listed in footnote (b) to Table 1 below.

- 42 -

Table 1 - Enzyme-Catalyzed Resolutions in Organic Solvents

Compound	Acyating agent and solvent	Enzyme	\bar{V} cross-linked enzyme crystal, $\times 10^3$	\bar{V} crude enzyme $\times 10^3$	\bar{V} Cross-linked enzyme crystal/ \bar{V} crude; equal protein	$\frac{E}{\text{Cross-linked enzyme crystal}}$	$\frac{E}{\text{crude enzyme}}$
Menthol [449mM]	VA[449mM] in toluene	CRL	1220	4	62	>>100	16
Ibuprofen [97mM]	n-amyl alcohol [460mM] in isooctane	CRL	57.5	0.13	90	>>100	7.2
Hydroxy hexanoic acid [532mM]	BuOH [1060mM] in toluene	CRL	85	2.2	7.9	55	2
Sec-phenethyl alcohol [200mM]	VA[200mM] in toluene	LPS	15000	30	1.7	>>100	>>100
Sulcatol [80mM]	VA[120mM] in toluene	LPS	6700	20	3.4	28	35
2-Octanol [80mM]	VA[120mM] in toluene	LPS	11700	44.5	2.6	9.8	9.4
Methyl tryptamine [200mM]	TFB [400mM] in tert-BuOH	ABL	12.5	2.9	3.6	41	46

a Crosslinked enzyme crystal concentrations were 4, 1, 10, 1.2, 0.4, 0.4 and 16 mg/ml.

b Crude enzyme concentrations were 20, 15, 50, 8.3, 40, 40 and 28 mg/ml, respectively, going from top to bottom of the table.

In Table 1, rates are displayed in $\mu\text{mol}/\text{min} \times \text{mg}$ at 25°C and concentrations are shown in 30 brackets.

- 43 -

In column 2 of the table, "VA" denotes vinyl acetate and "TFB" denotes trifluoroethyl butyrate. In column 3, the water content of the crude enzyme preparations was 9.3%, 2.5% and 5% for CRL, LPS and ABL, respectively.

In column 4 of Table 1, the water content of the crosslinked enzyme crystal formulations was 13.3%, 2.3% and 2.5% for CRL, LPS and ABL, respectively. The amount of surfactant in the final preparations of crosslinked enzyme crystal formulations were 16%, 40% and 50% (w/w) for CRL, LPS and ABL, respectively.

In column 6 of Table 1, the total protein content in the crude preparations of CRL, LPS and ABL were 10%, 0.7% and 7%, respectively. The protein content of crude ABL was 50% (w/w).

In column 7, reaction rates and enantio-selectivities were assayed by Cyclodex B, (R,R)Whelk-O1 (Ibuprofen) GC and Chiracel OJ (methyltryptamine) columns. E was calculated according to C.S. Chen et al., J. Am. Chem. Soc., 104, pp. 7294-99 (1982). See J.J. Lalonde et al., J. Am. Chem. Soc., 117, pp. 6845-52 (1995) for a discussion of the applicability of E for reactions affected by inhibition or catalyzed by crude enzymes.

In column 8, E_{app} was calculated as in an irreversible case based on the enantiomeric excess of the product at low conversion.

As demonstrated in Table 1, the crosslinked enzyme crystal formulations of three different enzymes (two lipases and subtilisin) and their crude counterparts exhibited markedly different activity in

- 44 -

the presence of organic solvents. The crosslinked enzyme crystal formulations were much more active than their crude counterparts on a weight basis (columns 4 and 5), and in all of the reactions, their specific activity per mg of protein was higher as well (column 6). Thus, in order to achieve the same activity in the resolution of menthol or sulcatol, for example, it is possible to use about 300 fold less catalyst. In the case of CRL and ABL, the striking difference in activities between the crude enzyme preparations and the crosslinked enzyme crystal formulations cannot be attributed to differences in water content. When crude CRL and ABL preparations were dried to the same water content as the crosslinked enzyme crystal formulations (13.3% for CRL and 2.5% for ABL) the activities changed by less than 12%.

We believe this to be the first demonstration that pure lipases can be extremely active in organic solvents in heterogeneous form. In addition, crosslinked CRL crystal formulations exhibit much higher enantioselectivity than the crude CRL preparation, containing contaminants with different selectivity (Table, entrees 1-3). In this case, the increased enantioselectivity of the crosslinked enzyme crystal formulation was due to the removal of competing hydrolases [Lalonde et al., supra].

The comparison of crosslinked enzyme crystal formulations with organic soluble lipase complexes is instructive. The specific activity of the LPS-crosslinked enzyme crystal in the resolution of phenethyl alcohol (19.5 $\mu\text{mol/min} \times \text{mg}$) and sulcatol

- 45 -

(1.48 $\mu\text{mol}/\text{min} \times \text{mg}$) is either similar to or higher than the activities achieved by soluble complexes in the same reactions [G. Ottolina et al., Biotechnol. Lett., 14, pp. 947-52 (1992) and Okahata et al. (1995),
5 supra]. However, the solubility of these complexes is limited in many organic solvents, thus making the high overall reaction rates difficult to achieve.

Crosslinked enzyme crystal formulations according to this invention, on the other hand, can be employed in
10 much higher quantities and, being insoluble, allow for easy separation and recycling.

We believe that surfactants play a critical role in the observed activity enhancement which characterizes the crosslinked enzyme crystal
15 formulations of this invention. See Example 9, *infra*.

A combination of effects may account for the dramatic increase in activity of pure lipases in crosslinked enzyme crystal form. For example, the presence of amphiphilic surfactants may help to
20 maintain a better water balance and native conformation of amphiphilic lipases, which in crude preparations can in part be achieved by different contaminants such as lipids, celite and other proteins. Finally, surfactants may simply facilitate the transfer of
25 hydrophobic substrate molecules through the layer of tightly bound water to the binding site of an enzyme. While more work is necessary to elucidate the exact mechanism of the effects of surfactants on the crosslinked enzyme crystal formulation activity, the
30 practical consequences of this phenomenon are immediately clear: high specific activity, purity and

- 46 -

stability of crosslinked enzyme crystal formulations result in high catalyst productivity in organic solvents.

Example 5 - Enzymatic Productivity

5 In order to demonstrate the productivity of crosslinked enzyme crystal formulations in organic solvents on a preparative scale we chose the resolution of sec-phenethyl alcohol (50 mmol; 6.1 g) with vinyl acetate (50 mmol; 4.3 g) in toluene (100 mL) catalyzed
10 by LPS-crosslinked enzyme crystals (1.3 mg solid; 1 mg protein). The reaction mixture was allowed to stir at room temperature for 16 hours, at which time the conversion reached 50%. The isolated yield of phenethyl acetate was 4.5 g (98.5% ee) giving the
15 volumetric productivity of 30 g/l and substrate to catalyst ratio of 4600. The productivity reached 8000 after 72 hours when 100 mmol sec-phenethyl alcohol was used.

 The high productivity of low molecular weight
20 synthetic catalysts is thought to be their key advantage over high molecular weight enzymes [E.N. Jacobsen and N.S. Finney, Chemistry & Biology, 1, pp. 85-90 (1994)]. This example clearly demonstrates that despite their high molecular weight and quite-unusual-
25 for-enzymes reaction medium, crosslinked enzyme crystal formulations are highly productive catalysts which compare favorably even with the best of synthetic catalysts.

Example 6 - Screening for Surfactants for LPS

- 47 -

Samples of crosslinked LPS crystals were prepared as in Example 1. Each sample was exposed to a different surfactant and then dried in the presence of the organic solvent used in Example 1. Drying was carried out in a 1 ml volume of surfactant and organic solvent. In addition, crosslinked LPS crystals were prepared as in Example 1, and dried as above, without exposure to a surfactant. Enzymatic activity was measured in the resolution of phenylethyl alcohol.

More specifically, 200 mM sec-phenethyl alcohol and 200 mM vinyl acetate in 1 ml toluene were added to 1.2 mg samples of dry crosslinked LPS crystals, some of which had been exposed to surfactants and some of which had not been exposed to surfactants. The reaction was allowed to proceed for 30 minutes, after which the % conversion was measured by gas chromatography. The results are shown in Table 2 below.

Table 2

20	<u>Surfactant</u>	% Conversion <u>in 30 Minutes</u>
	Anionic Surfactant: Triton QS-30 (Anionic)	0.5
	Aerosol 22	6
	Alkyl Sodium Sulfate (Niaproof) Type-8	1

- 48 -

20	<u>Surfactant</u>	<u>% Conversion in 30 Minutes</u>
	Alkyl (C9-C13) Sodium Sulfates (TEEPOL HB7)	<2
	Cationic Surfactant: Methyl trioctylammonium chloride (Aliquate 336)	12
	(EDT-20, ' PEG-10 tallow)	50
	Nonionic Surfactant: Polyoxyethylene Ethers 4 lauryl Ether (Brij 30)	14
	Octyl phenoxy polyethoxyethanol (Tritons)	
	Tx-15	16
	Tx-100	15
	Tx-114	6
	DF-16	37
	N-57	39
	DF-12	15
	CF-10	36
	CF-54	35
	Polyoxyethylenesorbitan Monolaurate (Tween 20)	10
	Sorbitan	
	Sesquioleate (Arlacel 83)	50

- 49 -

20	<u>Surfactant</u>	<u>% Conversion in 30 Minutes</u>
	Trioleate (Span 85)	10
	Polyglycol Ether (Tergitol)	
	Type NP-4	12
	Type NP-9	19
	Type TMN-10	3.5
	Type 15-S-3	50
	No Surfactant	3

Example 7 - Screening for Surfactants for ABL

Samples of crosslinked ABL crystals were prepared in Example 3. Each sample was exposed to a different surfactant and then dried in the presence of the same organic solvent used in Example 3. Drying was carried out in a 1 ml volume of surfactant and organic solvent. In addition, crosslinked ABL crystals were prepared as in Example 3, and dried as above, without exposure to a surfactant. Enzymatic activity was measured in the transesterification of N-Ac-PheOMe with n-propanol in isooctane.

More specifically, 1 ml (11 mg) of N-acetyl-L-phenylalanine methyl ester and 20% 1-propanol in 80% isooctane were added to 1 mg samples of dry crosslinked ABL crystals, some of which had been exposed to surfactants and some of which had not been exposed to surfactants. The reaction was allowed to proceed for 30 minutes, after which the % conversion was measured

- 50 -

by gas chromatography. The results are shown in Table 3 below.

Table 3

	<u>Surfactant</u>	<u>% Conversion</u>
5	Anionic Surfactant :	
	Aerosol 22	30
	dioctyl sulfosuccinate (AOT)	98
	Alkyl Sodium Sulfate (Niaproof)	
	Type-4	69
	Type-4	51
	Alkyl (C9-C13) Sodium Sulfates (TEEPOL HB7)	33
	Cationic Surfactant	
	Methyl trioctylammonium chloride (Aliquat 336)	93
	N,N',N'-polyoxyethylene (10)-N-tallow-1,3- diaminopropane	
	(EDT-20, ' PEG-10 tallow)	83
10	Nonionic Surfactant :	
	Polyoxyethylene Ethers:	
	4 lauryl Ether (Brij 30)	93
	23 lauryl Ether (Brij 35)	91
	Octyl phenoxy polyethoxyethanol (Tritons):	
	Tx-15	43
	Tx-100	87

- 51 -

<u>Surfactant</u>	<u>% Conversion</u>
Tx-114	89
Polyoxyethylenesorbitan:	
Monolaurate (Tween 20)	75
Sorbitan:	
Sesquioleate (Arlacel 83)	39
Trioleate (Span 85)	38
Polyglycol Ether (Tergitol):	
Type NP-4	89
Type NP-9	88
Type NP-35	95
Type TMN-6 (2,6,8, Trimethyl-4-nonyloxypoly- ethylenoxyethanol	85
Type TMN-10	91
Type 15-S-3	95
Type 15-S-40	88
No Surfactant	26

Example 8 - Screening for Surfactants for CRL

Samples of crosslinked CRL crystals were prepared as in Example 2. Each sample was exposed to a different surfactant and then dried in the presence of the same organic solvent used in Example 2. Drying was carried out in a 1 ml volume of surfactant and organic solvent. In addition, crosslinked CRL crystals were prepared as in Example 2, and dried as above, without exposure to a surfactant. Enzymatic activity was

- 52 -

measured in the transesterification of N-amyl alcohol with ethyl acetate in toluene.

More specifically, 184 nM n-amyl alcohol in ethyl acetate and 1 ml toluene was added to 2 mg
 5 samples of dry crosslinked CRL crystals, some of which had been exposed to surfactants and some of which had not been exposed to surfactants. The reaction was allowed to proceed for 30 minutes, after which the % conversion was measured by gas chromatography. The
 10 results are shown in Table 4 below.

Table 4

	<u>Surfactant</u>	<u>% Conversion</u>
15	Anionic Surfactant : Aerosol 22	12
	dioctyl sulfosuccinate (AOT)	13
	Triton QS-30	13
	Cationic Surfactant EDT-20, PEG-10 tallow	9
20	Nonionic Surfactant Octyl phenoxy polyethoxyethanol	
	TX-15	16
	TX-114	17
	DF-16	9
25	N-57	9
	NP-4	11

- 53 -

Polyoxyethylenesorbitan:

Monolaurate (Tween 20)	11
------------------------	----

Sorbitan:

Sesquioleate (Arlacel 83)	15
---------------------------	----

5	Polyglycol Ether (Tergitol)	
---	-----------------------------	--

Type TMN-6	16
------------	----

Type 15-S-3	12
-------------	----

Surfactant% Conversion

Type 15-S-40	10
--------------	----

10	No surfactant	0
----	---------------	---

Example 9 - Effect of Surfactants

The following example demonstrates the critical role of surfactants in the activity enhancement displayed by crosslinked enzyme crystal formulations according to this invention. We prepared crosslinked enzyme crystals as described in Examples 1-3, except that we dried them to a water content similar to that of the crosslinked enzyme crystal formulations of those examples, without the use of surfactants. Those water content levels were -- 13.3% water content for CRL; 1.7-2% water content for LPS and 2.2-2.4% water content for ABL.

For each enzyme sample, drying was carried out in the presence of the same solvent used for that particular enzyme in Example 1, 2 or 3, on a smaller (1 ml) scale. We then measured initial activity

- 54 -

levels, rather than % conversion, in the assays described in Examples 6-8 for the respective enzyme. We also measured the initial activity of each of the crosslinked enzyme crystal formulations of Examples 1-3 in the respective assay for that enzyme (CRL assay: Example 8; LPS assay: Example 6; ABL assay: Example 7). As compared with the initial activity levels of the crosslinked enzyme crystal formulations of Examples 1-3, the initial activity of the crosslinked enzyme crystals dried without surfactants were 19-fold (ABL), 79-fold (LPS) and more than 100-fold lower (CRL).

Table 5

15	<u>Enzyme</u>	<u>% moisture</u>	<u>initial activity (μmol/min x mg)</u>	<u>enzyme (mg/ml)</u>
	CRL dry no surfactant	13.5	0.0	3.5
20	CRL dry surfactant	13.2	0.25	2.0
	LPS dry no surfactant	2.3	0.09	5.3
	LPS dry surfactant	2.0	7.1	0.1

- 55 -

ABL dry no surfactant	2.4	0.03	6.6
ABL dry surfactant	2.2	0.58	0.3

5 % of surfactant in the crosslinked enzyme crystal formulations:

	<u>Enzyme</u>	<u>% Surfactant</u>
	CRL	25-30
	LPS	40-45
10	ABL	40-45

Example 10 - Screening of Surfactants

We used an alternate procedure to screen a number of anionic, cationic and nonionic surfactants for use in producing crosslinked enzyme crystal formulations according to this invention. In this screening procedure, enzyme activity of crosslinked enzyme crystal formulations prepared as in Examples 6-8 was measured after drying crosslinked enzyme crystals in a given surfactant in the presence of an organic solvent and after 12 days storage at room temperature. Activity of dry samples of CRL was measured in the transesterification of n-amyl alcohol with ethyl acetate in toluene, as described in Example 8. Activity of dry samples of ABL was measured in transesterification of N-Ac-PheOMe with n-propanol in isooctane, as described in Example 7. Activity of dry samples of LPS was measured in the resolution of phenylethyl alcohol, as described in Example 6. While enzymes exposed to several of the surfactants exhibited

- 56 -

high activity after drying, only a few maintained this high level after storage. In addition to the surfactants used in these examples, several others -- Tritons and dioctyl sulfosuccinate for CRL and dioctyl
5 sulfosuccinate and 4 lauryl ether for ABL -- provided crosslinked enzyme crystal formulations that exhibited high activity after storage.

While we have hereinbefore described a number of embodiments of this invention, it is apparent that
10 our basic constructions can be altered to provide other embodiments which utilize the processes and compositions of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the claims appended hereto rather than by
15 the specific embodiments which have been presented hereinbefore by way of example.

- 57 -

CLAIMS

I Claim:

1. A crosslinked protein crystal formulation, said formulation being characterized by activity in an organic solvent or an aqueous-organic solvent mixture which is at least about 1.7 times greater than the activity of the equivalent amount of said protein in either crude form or pure form.
2. The crosslinked protein crystal formulation according to claim 1, said formulation being characterized by activity in an organic solvent or an aqueous-organic solvent mixture which is between about 1.7 times and about 90 times greater than the activity of the equivalent amount of said protein in either crude form or pure form.
3. A crosslinked protein crystal formulation, said formulation being characterized by a specific activity per milligram of solid in an organic solvent or an aqueous-organic solvent mixture which is at least about 4.3 times greater than that of said protein in either crude form or pure form.
4. The crosslinked protein crystal formulation according to claim 3, said formulation being characterized by a specific activity per milligram of solid in an organic solvent or an aqueous-organic solvent mixture which is between about 4 times

- 58 -

and about 442 times greater than that of said protein in either crude form or pure form.

5. The crosslinked protein crystal formulation according to claim 3, said formulation being characterized by a specific activity per milligram of solid in an organic solvent or an aqueous-organic solvent mixture which is at least about 50 times greater than that of said protein in either crude form or pure form.

6. The crosslinked protein crystal formulation according to claim 3, said formulation being characterized by a specific activity per milligram of solid in an organic solvent or an aqueous-organic solvent mixture which is at least about 100 times greater than that of said protein in either crude form or pure form.

7. The crosslinked protein crystal formulation according to claim 3, said formulation being characterized by a specific activity per milligram of solid in an organic solvent or an aqueous-organic solvent mixture which is at least about 200 times greater than that of said protein in either crude form or pure form.

8. The crosslinked protein crystal formulation according to claim 3, said formulation being characterized by a specific activity per milligram of solid in an organic solvent or an aqueous-

- 59 -

organic solvent mixture which is at least about 300 times greater than that of said protein in either crude form or pure form.

9. A crosslinked protein crystal formulation, said formulation being characterized by activity in an organic solvent or an aqueous-organic solvent mixture which is at least about 19 times greater than the activity of crosslinked protein crystals containing no surfactant.

10. The crosslinked protein crystal formulation according to claim 9, said formulation being characterized by activity in an organic solvent or an aqueous-organic solvent mixture which is between about 19 times and about 100 times greater than the activity of crosslinked protein crystals containing no surfactant.

11. The crosslinked protein crystal formulation according to any one of claims 1, 3 or 9, wherein said formulation comprises a surfactant selected from the group consisting of anionic surfactants, cationic surfactants and non-ionic surfactants.

12. The crosslinked protein crystal formulation according to claim 11, wherein said surfactant comprises between about 10% and about 70% by weight of said formulation.

- 60 -

13. The crosslinked protein crystal formulation according to claim 12, wherein said surfactant comprises between about 25% and about 45% by weight of said formulation.

14. The crosslinked protein crystal formulation according to claim 11, wherein said anionic surfactant is selected from the group consisting of linear alkylbenzene sulphonate, alpha-olefin sulphonate, alkyl sulphate, alcohol ethoxy sulfate, carboxylic acids, sulfuric esters and alkane sulfonic acids.

15. The crosslinked protein crystal formulation according to claim 11, wherein said cationic surfactant is selected from the group consisting of amines, amine salts, sulfonium, phosphonium and quarternary ammonium compounds.

16. The crosslinked protein crystal formulation according to claim 11, wherein said non-ionic surfactant is selected from the group consisting of nonyl phenol ethoxylate, alcohol ethoxylate, sorbitan trioleate, non-ionic block copolymer surfactants, polyethylene oxide, polyethylene oxide derivatives of phenol alcohols and polyethylene oxide derivatives of fatty acids.

17. The crosslinked protein crystal formulation according to any one of claims 1, 3 or 9, wherein said protein crystal is a microcrystal.

- 61 -

18. The crosslinked protein crystal formulation according to any one of claims 1, 3 or 9, wherein said protein is an enzyme or an antibody.

19. The crosslinked protein crystal formulation according to claim 18, wherein said protein is an enzyme selected from the group consisting of hydrolases, isomerases, lyases, ligases, transferases and oxidoreductases.

20. The crosslinked protein crystal formulation according to claim 19, wherein said enzyme is a hydrolase.

21. The crosslinked protein crystal formulation according to claim 20, wherein said hydrolase is selected from the group consisting of thermolysin, elastase, esterase, lipase, nitrilase, hydantoinase, protease, asparaginase, urease and lysozyme.

22. The crosslinked protein crystal formulation according to any one of claims 1, 3 or 9, wherein said formulation is in lyophilized form.

23. The crosslinked protein crystal formulation according to any one of claims 1, 3 or 9, wherein said organic solvent is selected from the group consisting of diols, polyols, polyethers, water soluble polymers and mixtures thereof.

- 62 -

24. The crosslinked protein crystal formulation according to claim 23, wherein said organic solvent is selected from the group consisting of toluene, octane, tetrahydrofuran, acetone, pyridine, diethylene glycol, 2-methyl-2,4-pentanediol, poly(ethylene glycol), triethylene glycol, 1,4-butanediol, 1,2-butanediol, 2,3,-dimethyl-2,3-butanediol, 1,2-butanediol, dimethyl tartrate, monoalkyl ethers of poly(ethylene glycol), dialkyl ethers of poly(ethylene glycol), polyvinylpyrrolidone and mixtures thereof.

25. A method for producing a selected product in an organic solvent or an aqueous-organic solvent mixture using a protein, said method comprising the steps of:

(a) combining at least one substrate and at least one protein which acts upon the substrate in the presence of an organic solvent or an aqueous-organic solvent mixture, said protein being a crosslinked protein crystal formulation according to any one of claims 1, 3 or 9; and

(b) maintaining the combination produced in step (a) under conditions which permit said protein to act upon the substrate, thereby producing the selected product.

26. The method according to claim 25, wherein said product is selected from the group consisting of chiral organic molecules, peptides, carbohydrates and lipids.

- 63 -

27. The method according to claim 25, wherein said protein is an enzyme or an antibody.

28. The method according to claim 27, wherein said protein is an enzyme selected from the group consisting of hydrolases, isomerases, lyases, ligases, transferases and oxidoreductases.

29. The method according to claim 28, wherein said enzyme is a hydrolase.

30. The method according to claim 29, wherein said hydrolase is selected from the group consisting of thermolysin, elastase, esterase, lipase, nitrilase, hydantoinase, protease, asparaginase, urease and lysozyme.

31. The method according to claim 25, wherein said organic solvent is selected from the group consisting of diols, polyols, polyethers, water soluble polymers and mixtures thereof.

32. The method according to claim 31, wherein said organic solvent is selected from the group consisting of toluene, octane, tetrahydrofuran, acetone, pyridine, diethylene glycol, 2-methyl-2,4-pentanediol, poly(ethylene glycol), triethylene glycol, 1,4-butanediol, 1,2-butanediol, 2,3-dimethyl-2,3-butanediol, 1,2-butanediol, dimethyl tartrate, monoalkyl ethers of poly(ethylene glycol), dialkyl

- 64 -

ethers of poly(ethylene glycol), polyvinylpyrrolidone, and mixtures thereof.

33. A method for increasing the activity of crosslinked protein crystals in an organic solvent or a mixed aqueous-organic solvent mixture, said method comprising the steps of:

(a) combining the crosslinked protein crystals with a surfactant to produce a combination; and

(b) drying the combination of crosslinked protein crystals and surfactant in the presence of an organic solvent to form a crosslinked protein crystal formulation.

34. The method according to claim 33, wherein, in step (a), the combination comprises a weight ratio of crosslinked protein crystals to surfactant between about 1:1 and about 1:5.

35. The method according to claim 34, wherein, in step (a), the combination comprises a weight ratio of crosslinked protein crystals to surfactant between about 1:1 and about 1:2.

36. The method according to claim 33, wherein, in step (a), the crosslinked protein crystals and the surfactant are combined for a period of time between about 5 minutes and about 24 hours.

- 65 -

37. The method according to claim 36, wherein, in step (a), the crosslinked protein crystals and the surfactant are combined for a period of time between about 30 minutes and about 24 hours.

38. The method according to claim 33, wherein the surfactant comprises between about 10% and about 70% by weight of the crosslinked protein crystal formulation produced in step (b).

39. The method according to claim 38, wherein the surfactant comprises between about 25% and about 45% by weight of the crosslinked protein crystal formulation produced in step (b).

40. The method according to claim 33, wherein said surfactant is selected from the group consisting of anionic surfactants, cationic surfactants and non-ionic surfactants.

41. The method according to claim 40, wherein said anionic surfactant is selected from the group consisting of linear alkylbenzene sulphonate, alpha-olefin sulphonate, alkyl sulphate, alcohol ethoxy sulfate, carboxylic acids, sulfuric esters and alkane sulfonic acids.

42. The method according to claim 40, wherein said cationic surfactant is selected from the group consisting of amines, amine salts, sulfonium, phosphonium and quarternary ammonium compounds.

- 66 -

43. The method according to claim 40, wherein said non-ionic surfactant is selected from the group consisting of nonyl phenol ethoxylate, alcohol ethoxylate, sorbitan trioleate, non-ionic block copolymer surfactants, polyethylene oxide, polyethylene oxide derivatives of phenol alcohols and polyethylene oxide derivatives of fatty acids.

44. The method according to claim 40, wherein said protein is an enzyme or an antibody.

45. The method according to claim 44, wherein said protein is an enzyme selected from the group consisting of hydrolases, isomerases, lyases, ligases, transferases and oxidoreductases.

46. The method according to claim 45, wherein said enzyme is a hydrolase.

47. The method according to claim 46, wherein said hydrolase is selected from the group consisting of thermolysin, elastase, esterase, lipase, asparaginase, nitrilase, hydantoinase, protease, urease and lysozyme.

48. The method according to claim 40, wherein wherein said organic solvent is selected from the group consisting of diols, polyols, polyethers, water soluble polymers and mixtures thereof.

- 67 -

49. The method according to claim 48, wherein said organic solvent is selected from the group consisting of toluene, octane, tetrahydrofuran, acetone, pyridine, diethylene glycol, 2-methyl-2,4-pentanediol, poly(ethylene glycol), triethylene glycol, 1,4-butanediol, 1,2-butanediol, 2,3,-dimethyl-2,3-butanediol, 1,2-butanediol, dimethyl tartrate, monoalkyl ethers of poly(ethylene glycol), dialkyl ethers of poly(ethylene glycol), polyvinylpyrrolidone and mixtures thereof.

50. A method for separating a substance from a sample comprising an organic solvent or an aqueous-organic solvent mixture comprising the steps of:

- (a) contacting the sample with a
- 5 crosslinked protein crystal formulation according to any one of claims 1, 3 or 9, under conditions which permit said protein to bind with any said substance in said sample to form a complex; and
- (b) separating said complex from said
- 10 sample.

51. The method according to claim 50, wherein said protein is an enzyme or an antibody.

52. The method according to claim 50, wherein said crosslinked protein crystal formulation is

15 linked to a solid support.

- 68 -

53. The method according to claim 50,
wherein said solid support is an affinity column or
bead.

54. A method for carrying out chromatography
5 of a sample in the presence of an organic solvent or an
aqueous-organic solvent mixture comprising the steps
of:

(a) contacting said sample with a
crosslinked protein crystal formulation according to
10 any one of claims 1, 3 or 9, under conditions which
permit the components of said sample to bind with said
protein; and

(b) collecting said components as
separate fractions.

15 55. The method according to claim 54,
wherein said protein is an enzyme or an antibody.

56. The method according to claim 54,
wherein said crosslinked protein crystal formulation is
in a packed chromatography column.

20 57. The method according to claim 54,
wherein said chromatography is selected from the group
consisting of size exclusion chromatography, affinity
chromatography and chiral chromatography.

58. A biosensor for detecting an analyte of
25 interest in a sample, comprising:

- 69 -

(a) a crosslinked protein crystal formulation according to any one of claims 1, 3 or 9, wherein said protein has the activity of acting on the analyte of interest or on a reactant in a reaction in which the
5 analyte of interest participates; and

(b) a retaining means for said crosslinked protein crystal formulation, said retaining means comprising a material which allows contact between said crosslinked protein crystal formulation and a sample,
10 said sample containing either (1) the analyte upon which the protein acts or (2) a reactant in a reaction in which the analyte participates.

59. The biosensor according to claim 58, said biosensor further comprising a signal transducer
15 which produces a signal in the presence or absence of the analyte.

60. The biosensor according to claim 59, said biosensor further comprising means for detecting the activity of the protein on the analyte or reactant.

20 61. The biosensor according to claim 60, wherein said means for detecting the activity of the protein on the analyte or reactant is selected from the group consisting of pH electrodes, light sensing devices, heat sensing devices and means for detecting
25 electrical charge.

62. The biosensor according to claim 59, wherein said signal transducer is selected from the

- 70 -

group consisting of optical transducers, electrical transducers, electromagnetic transducers and chemical transducers.

63. An extracorporeal device for altering a
5 component of a sample comprising:

- (a) a crosslinked protein crystal formulation according to any one of claims 1, 3 or 9, wherein the protein has the activity of acting on the component or a reactant in a reaction in which the
10 component participates; and
- (b) a retaining means for said crosslinked protein crystal formulation, said retaining means comprising a material which allows contact between said crosslinked protein crystal formulation
15 and a sample, said sample containing either (1) the component upon which said protein acts or (2) a reactant in a reaction in which the component participates.

64. The extracorporeal device according to
20 claim 63, wherein said retaining means comprises a porous material on which said crosslinked protein crystal formulation is retained or a tube in which said crosslinked protein crystal formulation is present.

25 65. A reactive topical composition comprising a catalytically effective amount of a crosslinked protein crystal formulation according to any one of claims 1, 3 or 9 and a pharmaceutically acceptable carrier.

- 71 -

66. The reactive topical composition according to claim 65, wherein said crosslinked protein crystal formulation comprises between about 0.1% and about 99% by weight of said composition.

- 5 67. The reactive topical composition according to claim 66, wherein said crosslinked protein crystal formulation comprises between about 1% and about 10% by weight of said composition.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/08526

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N9/20 C12N11/00 C12Q1/00 A61K38/43

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y A	DE 43 44 211 A (BASF AG) 29 June 1995 see page 2, line 29 - page 3, line 6 see page 3, line 13 - line 29 & WO 95 17504 A cited in the application --- -/--	1,2, 11-16, 18-32 3-10,17, 33-49

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

- * "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- * "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- * "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * "&" document member of the same patent family

Date of the actual completion of the international search

18 September 1997

Date of mailing of the international search report

30.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/08526

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JIM L. LALONDE ET AL.: "Cross-linked crystals of Candida rugosa lipase: Highly efficient catalysts for the resolution of chiral esters" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 117, no. 26, 5 July 1995, DC US, pages 6845-6852, XP002041053 cited in the application see page 6849, left-hand column, last paragraph - page 6850, right-hand column, paragraph 2 ---	1,2, 11-16, 18-32
A	WO 92 02617 A (VERTEX PHARMACEUTICALS INCORPORATED) 20 February 1992 cited in the application see page 5, line 23 - page 7, line 23 see page 9, line 17 - page 12, line 15 see page 16, line 30 - page 19, line 21 see page 24, line 15 - page 25, line 11 see page 40, line 16 - page 42, line 6 see page 45, line 15 - page 52, line 29; examples 3-7 ---	1-67
P,X	KHALAF, NAZER ET AL: "Cross - Linked Enzyme Crystals as High Active Catalysts in Organic Solvents" J. AM. CHEM. SOC. (1996), 118(23), 5494-5495 CODEN: JACSAT;ISSN: 0002-7863, 1996, XP002041054 see the whole document ---	1-49
P,X	WANG, YI-FONG ET AL: "Cross - linked crystals of subtilisin: Versatile Catalysts for Organic Synthesis" ANN. N. Y. ACAD. SCI. (1996), 799(ENZYME ENGINEERING XIII), 777-783 CODEN: ANYAA9;ISSN: 0077-8923, 1996, XP002041055 see page 777, paragraph 2 - page 783, paragraph 1 -----	1-8, 25-32, 50-53

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/08526

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 4344211 A	29-06-95	WO 9517504 A	29-06-95
WO 9202617 A	20-02-92	AU 662104 B	24-08-95
		AU 8315491 A	02-03-92
		CA 2087730 A	04-02-92
		EP 0550450 A	14-07-93
		HU 65904 A	28-07-94
		HU 9500666 A	28-11-95
		LT 1077 A,B	25-04-95
		LV 10304 B	20-06-95
		NZ 264042 A	25-06-96
		SK 5993 A	07-07-93
		US 5618710 A	08-04-97